Company news

Hinova Pharmaceuticals, Inc. Class A (SSE:688302) news

Hinova Pharmaceuticals, Inc. Class A news releases on 6ix. Latest, Sep 24, 2026: "HINOVA PHARMACEUTICALS INC."Announcement on the Board Secretary's Receipt…

Hinova Pharmaceuticals, Inc. Class A (SSE:688302) news

Press releases & updates

"HINOVA PHARMACEUTICALS INC."Announcement on the Board Secretary's Receipt of the Qualification Training Certificate and Official Assumption of Duties

"HINOVA PHARMACEUTICALS INC."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"HINOVA PHARMACEUTICALS INC."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"HINOVA PHARMACEUTICALS INC."Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTER CO., LTD.

"HINOVA PHARMACEUTICALS INC."Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors

"HINOVA PHARMACEUTICALS INC."Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate Cancer

Announcement on Reply to Inquiry Letter for Information Disclosure Supervision of 2025 Annual Report

Announcement on Voluntary Disclosure of Final Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of Interim Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

Notice on Convening the 2025 Annual General Meeting

Announcement on Change of Sponsor Representative

Announcement on Voluntary Disclosure of Completion of Inclusion of All Participants in Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

Announcement on Preliminary Earnings Estimate for 2025

Announcement on the Company's Successful GMP Compliance Inspection and the Amendment of Its Drug Manufacturing License

Earnings Preannouncement for 2025

Announcement on Resolutions of the 16th Meeting of the 2nd Board of Directors

Announcement on Resolutions of the 15th Meeting of the 2nd Board of Directors

Announcement on the Voluntary Disclosure of the Inclusion of Deutenzalutamide Soft Capsules in the 2025 National Medical Insurance Drug Catalog

Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Batch of Participants in Phase II Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Resignation of Independent Director and By-election of Independent Director, and Adjustment of Members of Special Committees of the Board of Directors

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

Announcement on Result of Shareholding Reduction by Shareholder

2025 Semi-annual Report

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 5%

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%

Announcement on Voluntary Disclosure of Approval of New Drug Marketing Application for Deutenzalutamide Soft Capsules

Announcement on Convening the Q1 2025 Performance Briefing

Announcement on Share Reduction Plan for Shareholders

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Application for Mortgage Loan from Bank

Announcement on Resolution of the 8th Meeting of the 2nd Board of Supervisors

Announcement on Listing and Circulation of Partial Restricted Stocks in Initial Public Offering

Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Share Reduction

Indicative Announcement on Change in Equity of Shareholders Holding More than 5% of Shares

Announcement on Preliminary Earnings Estimate for 2024

Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of HP515 Tablets in China

Annual Earnings Preannouncement for 2024

Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of Oral PROTAC Drug HP568 Tablets in China

Announcement on Extension of Some Investment Projects Financed by Raised Funds from Initial Public Offering of Shares

Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

Announcement on Share Reduction Plan for Shareholders with Over 5% Shares

Announcement on Convening the Q3 2024 Performance Briefing

Report for Q3 2024

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

Announcement on Expiration of the Shareholding Reduction Plan for Shareholders with Over 5% Shares and Equity Change Reaching 1%